C4 Therapeutics Inc
CCCC
Market Cap$467.88M
Close$
$-1.23
120.6% downside
Current Fair Value
120.6% downsideOvervalued by 120.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $467.88 Million |
|---|---|
| Enterprise Value | $279.41 Million |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-2.67 |
| Beta | 3.34 |
| Outstanding Shares | 68,805,786 |
| Avg 30 Day Volume | 1,284,216 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -3.53 |
|---|---|
| PEG | 19.13 |
| Price to Sales | - |
| Price to Book Ratio | 2.0 |
| Enterprise Value to Revenue | 13.95 |
| Enterprise Value to EBIT | -2.11 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.25 |
| Debt to Equity | 0.27 |
Revenue Sources
No data
ESG Score
No data
About C4 Therapeutics Inc
99 employeesC4 Therapeutics is a biopharmaceutical company focused on harnessing the body’s natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer and o...